Paratek Pharma Reports Third Quarter 2016 Financial Results and Provides Clinical Updates
BOSTON, Nov. 02, 2016 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline chemistry, today reported financial results for the quarter ended September 30, 2016. The company also reported the completion and top-line results of a Phase 1b study of omadacycline in patients with urinary tract infections, as well as the completion of several important clinical and manufacturing requirements for its planned NDA submission.
Phase 1b UTI Pharmacokinetic Results
In this clinical study, patients with uncomplicated UTI received either IV-to-oral or oral-only regimens of omadacycline over a period of five days. Results showed that omadacycline achieved high steady state concentrations in urine for all treatment regimens, demonstrating proof-of-principle for the use of omadacycline in UTI.
Phase 1b UTI Pharmacokinetic Results
In this clinical study, patients with uncomplicated UTI received either IV-to-oral or oral-only regimens of omadacycline over a period of five days. Results showed that omadacycline achieved high steady state concentrations in urine for all treatment regimens, demonstrating proof-of-principle for the use of omadacycline in UTI.